Crescita Therapeutics Inc. (CTX.TO)
CAD 0.57
(1.79%)
CAD 0.57
(1.79%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.98 Million CAD | -330.39% |
| 2022 | 862 Thousand CAD | 178.01% |
| 2021 | -1.1 Million CAD | -3086.49% |
| 2020 | 37 Thousand CAD | -98.01% |
| 2019 | 1.85 Million CAD | -22.58% |
| 2018 | 2.39 Million CAD | 120.9% |
| 2017 | -11.46 Million CAD | 23.31% |
| 2016 | -14.94 Million CAD | 3.24% |
| 2015 | -15.44 Million CAD | -5.8% |
| 2014 | -14.6 Million CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -926 Thousand CAD | -47.92% |
| 2024 Q1 | -626 Thousand CAD | -317.33% |
| 2023 Q4 | -150 Thousand CAD | 88.3% |
| 2023 FY | -1.98 Million CAD | -330.39% |
| 2023 Q3 | -1.28 Million CAD | -356.23% |
| 2023 Q2 | -281 Thousand CAD | -2.93% |
| 2023 Q1 | -273 Thousand CAD | -123.17% |
| 2022 Q1 | -572 Thousand CAD | -160.66% |
| 2022 FY | 862 Thousand CAD | 178.01% |
| 2022 Q4 | 1.17 Million CAD | 504.1% |
| 2022 Q3 | 195 Thousand CAD | 171.17% |
| 2022 Q2 | -274 Thousand CAD | 52.1% |
| 2021 FY | -1.1 Million CAD | -3086.49% |
| 2021 Q3 | -900 Thousand CAD | -26.4% |
| 2021 Q4 | 943 Thousand CAD | 204.78% |
| 2021 Q1 | -436 Thousand CAD | 26.35% |
| 2021 Q2 | -712 Thousand CAD | -63.3% |
| 2020 Q4 | -592 Thousand CAD | -114.07% |
| 2020 Q2 | -3.08 Million CAD | -524.49% |
| 2020 FY | 37 Thousand CAD | -98.01% |
| 2020 Q1 | -494 Thousand CAD | -2.28% |
| 2020 Q3 | 4.2 Million CAD | 236.4% |
| 2019 Q3 | 88 Thousand CAD | -96.01% |
| 2019 Q4 | -483 Thousand CAD | -648.86% |
| 2019 FY | 1.85 Million CAD | -22.58% |
| 2019 Q1 | 42 Thousand CAD | -98.65% |
| 2019 Q2 | 2.2 Million CAD | 5157.14% |
| 2018 Q3 | 369 Thousand CAD | 155.82% |
| 2018 Q4 | 3.11 Million CAD | 743.36% |
| 2018 Q1 | -424 Thousand CAD | 94.86% |
| 2018 FY | 2.39 Million CAD | 120.9% |
| 2018 Q2 | -661 Thousand CAD | -55.9% |
| 2017 Q1 | -3.19 Million CAD | 22.08% |
| 2017 Q4 | -8.25 Million CAD | -1509.55% |
| 2017 FY | -11.46 Million CAD | 23.31% |
| 2017 Q3 | -513 Thousand CAD | -202.6% |
| 2017 Q2 | 500 Thousand CAD | 115.66% |
| 2016 Q2 | -3.07 Million CAD | 49.17% |
| 2016 FY | -14.94 Million CAD | 3.24% |
| 2016 Q4 | -4.09 Million CAD | -139.23% |
| 2016 Q1 | -6.05 Million CAD | -37.53% |
| 2016 Q3 | -1.71 Million CAD | 44.37% |
| 2015 Q4 | -4.4 Million CAD | -33.36% |
| 2015 Q2 | -5.44 Million CAD | -137.25% |
| 2015 Q3 | -3.3 Million CAD | 39.34% |
| 2015 FY | -15.44 Million CAD | -5.8% |
| 2015 Q1 | -2.29 Million CAD | 0.0% |
| 2014 FY | -14.6 Million CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Aurora Cannabis Inc. | -69.32 Million CAD | 97.135% |
| Avicanna Inc. | -8.74 Million CAD | 77.285% |
| Avant Brands Inc. | -5.07 Million CAD | 60.828% |
| Cardiol Therapeutics Inc. | -28.12 Million CAD | 92.939% |
| Knight Therapeutics Inc. | -16.83 Million CAD | 88.203% |
| MediPharm Labs Corp. | -13.08 Million CAD | 84.82% |
| OrganiGram Holdings Inc. | -229.47 Million CAD | 99.135% |
| Canopy Growth Corporation | -657.26 Million CAD | 99.698% |
| Willow Biosciences Inc. | -13.02 Million CAD | 84.757% |
| Auxly Cannabis Group Inc. | -44.51 Million CAD | 95.538% |